Erik S. Lesser/Getty Images News Merck & Co ( NYSE: MRK ) shares traded in the green on Monday, making it the seventh straight day of gains. The stock closed up 0.
63% at $131.49. MRK has risen 21.
1% in the last 12 months and 0.72% in the last one month. YTD, the stock has outperformed the broader S&P 500 market, which rose 12.
1% as compared to the company’s YTD gain of 19.86%. Looking at Seeking Alpha's Quant Ratings, this New Jersey based pharma company has a Hold rating with a score of 3.
44 out of 5. When it comes to Wall Street analysis, 18 out of 28 analysts recommend a Strong Buy, 6 rate it as a Buy, 3 rate it as a Hold and 1 rates it as a Sell. Seeking Alpha analysts have a Buy rating on the company.
According to SA analyst Leo Nelissen, “Merck's blockbuster drug, Keytruda, is revolutionizing cancer treatment, showing remarkable results in early-stage cancers. With a robust pipeline and significant growth projections, Merck is well-positioned for long-term success.” Merck reported better than expected Q1 2024 financials and raised its full-year outlook amid ~20% YoY growth in sales for Keytruda.
.
